Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics Inc has achieved significant milestones, including FDA clearance for a Phase 2a study and the initiation of the ALSTARS Phase 2 trial for ALS, showcasing its operational effectiveness and commitment to advancing its Treg therapies in neurodegenerative diseases. Promising early clinical data indicates biomarker improvement and disease progression signals, reinforcing the potential efficacy of its proprietary therapies and validating the underlying Treg biology. With a robust cash position of $46.8 million, the company is well-funded to support its operations through the second half of 2027, enhancing its strategic positioning for continued growth in a competitive biotechnology landscape.

Bears say

Coya Therapeutics Inc faces significant challenges that negatively impact its stock outlook, including the potential for delays in regulatory approval and commercial uptake for its lead product, COYA 302, particularly in conditions such as ALS and Alzheimer's disease. The company is also experiencing risks related to its pipeline candidates, with setbacks threatening to hinder progress and advancement into pivotal development stages. Additionally, issues surrounding partnerships and the possibility of medium-term equity dilution present further pressures on Coya's financial stability and market performance.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.